Patients
with
differentiated
thyroid
cancer
usually
present
early-stage
disease
and
undergo
surgery
followed
by
adjuvant
radioactive
iodine
ablation,
resulting
in
excellent
clinical
outcomes
prognosis.
However,
a
minority
of
patients
relapse
metastatic
disease,
eventually
develop
refractory
(RAIR).
In
the
past
there
were
limited
ineffective
options
for
systemic
therapy
RAIR,
but
over
last
ten
to
fifteen
years
emergence
tyrosine
kinase
inhibitors
(TKIs)
has
provided
important
new
avenues
treatment
these
patients,
that
are
focus
this
review.
Currently,
Lenvatinib
Sorafenib,
multitargeted
TKIs,
represent
standard
first-line
RAIR
carcinoma,
while
Cabozantinib
is
second-line
option.
Furthermore,
targeted
therapies
specific
targetable
molecular
abnormalities
include
Latrectinib
or
Entrectinib
NTRK
gene
fusions
Selpercatinib
Pralsetinib
RET
fusions.
Dabrafenib
plus
Trametinib
currently
only
have
tumor
agnostic
approval
USA
BRAF
V600E
mutations,
including
cancer.
Redifferentiation
an
area
active
research,
promising
initial
results,
immunotherapy
studies
checkpoint
combination
underway.
Journal of Personalized Medicine,
Год журнала:
2023,
Номер
13(5), С. 813 - 813
Опубликована: Май 11, 2023
Thyroid
cancers
require
complex
and
heterogeneous
therapies
with
different
impacts
on
renal
function.
In
our
systematic
literature
review,
we
analyzed
several
aspects:
function
assessment,
the
impact
of
radiotherapy
thyroid
surgery
kidney
functioning,
mechanisms
nephrotoxicity
chemotherapy,
targeted
immunologic
drugs.
Our
study
revealed
that
cancer
therapy
can
be
a
limiting
factor
in
all
radiotherapy,
surgery,
pharmacological
approaches.
It
is
advisable
to
conduct
careful
nephrological
follow-up
imposing
application
body
surface
based
estimated
Glomerular
Filtration
Rate
(eGFR)
formulas
for
purpose
an
early
diagnosis
treatment
failure,
guaranteeing
continuation
patients.
Gels,
Год журнала:
2024,
Номер
10(6), С. 352 - 352
Опубликована: Май 21, 2024
The
current
research
investigated
the
use
of
gelatin
nanoparticles
(GNPs)
for
enhancing
cytotoxic
effects
nivolumab,
an
immune
checkpoint
inhibitor.
unique
feature
GNPs
is
their
biocompatibility
and
functionalization
potential,
improving
delivery
efficacy
immunotherapeutic
drugs
with
fewer
side
compared
to
traditional
treatments.
This
exploration
represents
innovative
direction
in
advancement
nanomedicine
oncology.
Nivolumab-loaded
were
prepared
characterized.
optimum
formulation
had
a
particle
size
191.9
±
0.67
nm,
polydispersity
index
0.027
0.02,
drug
entrapment
54.67
3.51%.
A
co-culture
experiment
involving
A549
target
cells
effector
Jurkat
treated
free
nivolumab
solution,
nivolumab-loaded
GNPs,
demonstrated
that
latter
significant
improvements
inhibition
rate
by
scoring
87.88
2.47%
drug-loaded
against
60.53
3.96%
solution.
lower
IC50
value,
0.41
0.01
µM,
solution
(1.22
0.37
µM)
at
72
h.
results
indicate
administering
augmented
cytotoxicity
cell
activity
treatment.
Iranian Journal of Public Health,
Год журнала:
2024,
Номер
unknown
Опубликована: Июль 13, 2024
Background:
BRAF
V600E
mutation
is
proved
critical
in
the
progression
and
invasion
of
thyroid
cancer,
as
a
prognostic
biomarker.
As
anaplastic
cancer
(ATC)
rare
aggressive
form
this
study
was
conducted
to
provide
view
on
prevalence
well
best
molecular
diagnostic
method
ATC
patients.
Methods:
A
comprehensive
literature
search
performed
from
their
inception
Oct
2022
PubMed,
Scopus,
Google
Scholar,
Web
Science
(WoS).
The
data
were
extracted.
Moreover,
feature
available
tools
extracted
measure
sensitivity
specificity.
To
pool
data,
we
used
meta-proportion
analysis
meta-analysis
determine
specificity
immunohistochemistry
detecting
among
patients
with
ATC.
Results:
Overall,
34
studies
included
meta-analysis.
incidence
shown
33%
978
IHC
detected
78.9%
(95%CI:
60.1-97.2),
69.7%
41.2-98.1),
respectively.
Conclusion:
had
an
acceptable
profile
for
diagnosis
clinical
trials
may
be
helpful
choosing
proper-targeted
therapy
strategies
Cellular and Molecular Life Sciences,
Год журнала:
2021,
Номер
78(15), С. 5827 - 5846
Опубликована: Июнь 21, 2021
Abstract
Stromal
interaction
molecule
1
(STIM1)
and
the
ORAI1
calcium
channel
mediate
store-operated
entry
(SOCE)
regulate
a
multitude
of
cellular
functions.
The
identity
function
these
proteins
in
thyroid
cancer
remain
elusive.
We
show
that
STIM1
expression
is
elevated
cell
lines,
compared
to
primary
cells.
Knock-down
or
attenuated
SOCE,
reduced
invasion,
promigratory
sphingosine
1-phosphate
vascular
endothelial
growth
factor-2
receptors
ML-1
Cell
proliferation
was
knock-down
cells
due
increased
G1
phase
cycle
enhanced
cyclin-dependent
kinase
inhibitory
p21
p27.
protein
upregulated
tissue,
normal
tissue.
Downregulation
restored
stimulating
hormone
receptor,
specific
iodine
uptake.
knockdown
were
more
susceptible
chemotherapeutic
drugs,
significantly
tumor
Zebrafish.
Furthermore,
STIM1-siRNA-loaded
mesoporous
polydopamine
nanoparticles
invasion
Taken
together,
our
data
suggest
potential
diagnostic
therapeutic
target
for
treatment
cancer.
Patients
with
differentiated
thyroid
cancer
usually
present
early-stage
disease
and
undergo
surgery
followed
by
adjuvant
radioactive
iodine
ablation,
resulting
in
excellent
clinical
outcomes
prognosis.
However,
a
minority
of
patients
relapse
metastatic
disease,
eventually
develop
refractory
(RAIR).
In
the
past
there
were
limited
ineffective
options
for
systemic
therapy
RAIR,
but
over
last
ten
to
fifteen
years
emergence
tyrosine
kinase
inhibitors
(TKIs)
has
provided
important
new
avenues
treatment
these
patients,
that
are
focus
this
review.
Currently,
Lenvatinib
Sorafenib,
multitargeted
TKIs,
represent
standard
first-line
RAIR
carcinoma,
while
Cabozantinib
is
second-line
option.
Furthermore,
targeted
therapies
specific
targetable
molecular
abnormalities
include
Latrectinib
or
Entrectinib
NTRK
gene
fusions
Selpercatinib
Pralsetinib
RET
fusions.
Dabrafenib
plus
Trametinib
currently
only
have
tumor
agnostic
approval
USA
BRAF
V600E
mutations,
including
cancer.
Redifferentiation
an
area
active
research,
promising
initial
results,
immunotherapy
studies
checkpoint
combination
underway.
